Details of Drug Off-Target (DOT)

General Information of Drug Off-Target (DOT) (ID: OT4MJUWB)

DOT Name	Transmembrane domain-containing protein TMIGD3 (TMIGD3)
Gene Name	TMIGD3
Related Disease	Bone osteosarcoma ( ) Osteosarcoma ( )
UniProt ID	TMIG3_HUMAN
3D Structure	Download 2D Sequence (FASTA) Download 3D Structure (PDB) Download
Sequence	MEGSPAGPIEQKEARWESSWEEQPDWTLGCLSPESQFRIPGLPGCILSFQLKVCFLPVMW LFILLSLALISDAMVMDEKVKRSFVLDTASAICNYNAHYKNHPKYWCRGYFRDYCNIIAF SPNSTNHVALRDTGNQLIVTMSCLTKEDTGWYWCGIQRDFARDDMDFTELIVTDDKGTLA NDFWSGKDLSGNKTRSCKAPKVVRKADRSRTSILIICILITGLGIISVISHLTKRRRSQR NRRVGNTLKPFSRVLTPKEMAPTEQM
Function	[Isoform 1]: Plays a suppressive role in osteosarcoma malignancy by inhibiting NF-kappa-B activity.
Tissue Specificity	Expressed in the lung and bone. Expressed at lower levels in osteosarcoma tissues (at protein level).

Molecular Interaction Atlas (MIA) of This DOT

2 Disease(s) Related to This DOT

Disease Name	Disease ID	Evidence Level	Mode of Inheritance
Bone osteosarcoma	DIST1004	Limited	Altered Expression	[1]
Osteosarcoma	DISLQ7E2	Limited	Altered Expression	[1]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This DOT

1 Drug(s) Affected the Gene/Protein Processing of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
Leflunomide	DMR8ONJ	Phase 1 Trial	Leflunomide increases the expression of Transmembrane domain-containing protein TMIGD3 (TMIGD3).	[2]
------------------------------------------------------------------------------------

References

1	Genome-wide RNAi screening identifies TMIGD3 isoform1 as a suppressor of NF-B and osteosarcoma progression.Nat Commun. 2016 Nov 25;7:13561. doi: 10.1038/ncomms13561.
2	Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.